Gordon R. B. Skinner
Corporate Officer/Principal bei Vaccine Research International Plc
Profil
Dr. Gordon R.
Skinner, MD, is a Director & Research Director at Grupo International, Inc. and a Managing Director at Vaccine Research International Plc.
He is on the Board of Directors at Grupo International, Inc. and Intracell Vaccines Ltd.
Dr. Skinner was previously employed as a Board Member & Research Director by HIV-VAC, Inc.
He received his undergraduate degree from the University of Glasgow, a doctorate degree from the University of Birmingham, and a doctorate degree from the University of Birmingham.
Aktive Positionen von Gordon R. B. Skinner
| Unternehmen | Position | Beginn |
|---|---|---|
Vaccine Research International Plc
 Vaccine Research International Plc Miscellaneous Commercial ServicesCommercial Services Vaccine Research International Plc is a British company that focuses on conducting clinical trials to evaluate the effectiveness of vaccine SA75 in preventing staphylococcal infections in hospital patients and the wider community. | Corporate Officer/Principal | 09.04.2010 |
Ehemalige bekannte Positionen von Gordon R. B. Skinner
| Unternehmen | Position | Ende |
|---|---|---|
HIV-VAC, Inc.
 HIV-VAC, Inc. Miscellaneous Commercial ServicesCommercial Services HIV-VAC, Inc. develops and markets proposed vaccine designed to combat HIV/AIDS. This proposed vaccine, which is called NFU.Ac.HIV, was developed by Dr. Gordon Skinner, director of research, through the University of Birmingham, in the U.K. The proposed vaccine was licensed to Intracell Vaccines Limited from the University of Birmingham. The company was founded in 1997 and is headquartered in Ontario, CA. | Technik-/Wissenschafts-/F&E-Leiter | 28.10.2010 |
| GRUPO INTERNATIONAL INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Intracell Vaccines Ltd.
 Intracell Vaccines Ltd. Medical SpecialtiesHealth Technology Intracell Vaccines Ltd. develops vaccines. The company is headquartered in Gaithersburg, MD. | Direktor/Vorstandsmitglied | - |
Ausbildung von Gordon R. B. Skinner
| University of Glasgow | Undergraduate Degree |
| University of Birmingham | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GRUPO INTERNATIONAL INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
HIV-VAC, Inc.
HIV-VAC, Inc. Miscellaneous Commercial ServicesCommercial Services HIV-VAC, Inc. develops and markets proposed vaccine designed to combat HIV/AIDS. This proposed vaccine, which is called NFU.Ac.HIV, was developed by Dr. Gordon Skinner, director of research, through the University of Birmingham, in the U.K. The proposed vaccine was licensed to Intracell Vaccines Limited from the University of Birmingham. The company was founded in 1997 and is headquartered in Ontario, CA. | Commercial Services |
Intracell Vaccines Ltd.
Intracell Vaccines Ltd. Medical SpecialtiesHealth Technology Intracell Vaccines Ltd. develops vaccines. The company is headquartered in Gaithersburg, MD. | Health Technology |
Vaccine Research International Plc
Vaccine Research International Plc Miscellaneous Commercial ServicesCommercial Services Vaccine Research International Plc is a British company that focuses on conducting clinical trials to evaluate the effectiveness of vaccine SA75 in preventing staphylococcal infections in hospital patients and the wider community. | Commercial Services |
